European Headache Alliance

Tag Archives: Novartis

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities…
Read More